Methodological study on drug susceptibility testing for Mycobacterium

Abstract

Abstract: Objective To analyze the comparability between proportion method and absolute concentration method in drug susceptibility testing (DST).Methods 453 isolates from nationwide epidemiological survey were subjected to susceptibility testing against 4 anti tuberculosis drugs using both proportion method and absolute concentration method.Results The resistance to each of 4 drugs in 402 M.tuberculosis isolates did not show statistically significant difference between two methods.In 51 NTM isolates,only was the resistance to EMB significantly higher in proportion method than in absolute concentration method.The accordance rate between two Methods was 96.2%、97.1%,98.7% and 96.9% for INH,SM,RFP and EMB respectively.Conclusion The accordance between proportion method and absolute concentration method is high,and the Results obtained by using proportion method are comparable with both international standard and previous data of our country.

Key words: Mycobacterium tuberculosis, Drug resistance, Methodology

LIU Yu hong,JIANG Guang lu,ZHAO Li ping,et al.. Methodological study on drug susceptibility testing for Mycobacterium[J]. Chinese Journal of Antituberculosis, 2003, 25(1): 16-20.

References

[1] WHO/IU AT. Guidelines for surveillance of drug resistance in tuberculosis [M]. WHCVTB, 1996.21，17
[2] Department of Microbiology, Korean Institute of Tuberculosis, Korean National Tuberculosis Association. Tuberculosis laboratory service[M].1997.71～81.
[3] 中国防痨协会.结核病诊断细菌学检验规程[J].中国防痨杂志，1996,18(1):28～31.
[4] 中华人民共和国卫生部，1990全国结核病流行病学抽样调查资料汇编[M].北京：中华人民共和国，1990,66～69.
[5] Patricia T K, George P, Kubica. Public Health Mycobecteriology, a guide for the level ID laboratory [M]. U.S. Department of Health and Human Service/Public Health Service/Centers of Disease Control. Altlanta,Georgia 30333,1985:162～182.
[6] Canetti G,Grosset Jt Hauduroy P,et al. Mycobacteria： Laboratory methods for testing drug sensitivity and resistance [J]. Bull WHO. 1963,29:565～578.
[7] Canetti G, Wallace Fox, Khomenko A, et al. Advances in techniques of testing Mycobacterial drug sensitivity, and the use of sensitivity tests in tuerculosis control programmes [J]. Bull. WHO 1969,41,21～43.
[8] 全国结核病流调技术指导组，第四次全国流行病学抽样调查工作手册[M].2000.
[9] Leonid Heifets. Qualitative and quantitative drug-susceptibility tests in mycobacteriology [J]. Am Rev Respir Dis,1988,137:1217～1222.
[10] Canetti G，Wallace Fox, Khomenko A, et al. Advances in techniques of testing Mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes [J]. Bull WHO 1969,41,21～43.
[11] Casal M. Laboratory approaches to mycobacterial susceptibility to antibiotics [J] .Rev Esp Quimioterap. 1993,8(3): 184～189.
[12] 刘宇红，王甦民，那希宽.比例法测试结核分支杆菌药物敏感性的探讨[J].中华结核和呼吸杂志，2000,23(2):89～92.
[13] 中华人民共和国卫生部药典委员会.中华人民共和国药典(1990年版）[M].北京：化学工业出版社、人民卫生出版社，1990.429～430.

[1]	Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768.
[2]	YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806.
[3]	ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813.
[4]	ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820.
[5]	DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831.
[6]	QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879.
[7]	SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717.
[8]	BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724.
[9]	ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740.
[10]	MA Jin-bao, REN Fei, ZENG Ling-cheng, CHEN Ming-wei. Analysis of drug susceptibility of 680 patients with multidrug-resistant tuberculosis in Xi’an City from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 609-613.
[11]	LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488.
[12]	ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365.
[13]	ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379.
[14]	YANG Han,YANG Jing-fen,WU Hao,CUI Xiao-li,DANG Li-yun. Value of MicroDST test in detecting sensitivity of first-line anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 380-384.
[15]	GAO Tian-hui,SHU Wei,GAO Jing-tao,LU Yu,LI Qi. Analysis of clarithromycin resistance and its influencing factors in 254 patients with drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 259-265.